Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases

TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche’s LightCycler PCR instruments TIB Molbiol will continue to focus on the research and development of assays that rapidly address critical healthcare needs including biological threats Basel , 1 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has completed its share purchase agreement to acquire 100 percent of the outstanding shares of TIB Molbiol Group . TIB Molbiol …

Read the source article at Stock Market Quotes and News
2021-12-01 06:01:10